20 June 2013
Keywords: Novartis, Biotechnology production facility, Singapore, Investment
Article | 01 November 2012
Swiss drug major Novartis (NOVN: VX) says it plans to invest over $500 million in the construction of a new state-of-the-art ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
1 November 2012
19 June 2013
© 2013 thepharmaletter.com